Tectin, a drug derived from the puffer fish, also known as blow fish or fugu, has been developed by Vancouver-based International Wex Technologies Inc. to block slow sodium channel nocicipetive pain fibers in a highly selective manner. Results from a recently completed open-label Phase IIa dose were presented in a podium presentation by the lead investigator, Dr. Neil Hagen, during the 2nd Joint Scientific Meeting of the American Pain Society and the Canadian Pain Society that was held in Vancouver, B.C, on May 6-9, 2004.
The Phase IIa results demonstrate that TectinTM, administered intramuscularly for four days at the studied doses, is well tolerated and can relieve refractory cancer pain for up to two weeks in some patients. Consistent with the interim analysis, the final results show that almost three-quarters (72%) of cancer pain patients experienced a clinically meaningful analgesic response.
Based on these promising results, the Company was encouraged to pursue a larger trial to further confirm the effectiveness of the compound. The current trial is a multicentre, randomized, double-blind and placebo-controlled study designed to compare the efficacy and safety of TectinTM versus placebo in moderate to severe inadequately controlled cancer-related pain.
The study is being led by two nationally respected leaders in cancer pain assessment and management, Dr. Neil Hagen, Head of the Division of Palliative Medicine, Department of Oncology at the University of Calgary and Dr. Bernard Lapointe, Chief of the Palliative Care Division of the Je
'"/>
Contact: Don Evans
don@wextech.ca
604-683-8880
WEX Pharmaceuticals Inc.
11-May-2004